email article
In the 21 months since the FDA granted accelerated approval to atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) for locally advanced or metastatic PD-L1 positive triple-negative breast cancer (TNBC), Halle Moore, MD, of Cleveland Clinic Taussig Cancer Center in Ohio, has seen a definite uptake in use of the regimen.
"At our institution we routinely check upfront for PD-L1 expression, and unless it is contraindicated or a patient is going on a clinical trial, we recommend the combination in eligible patients," Moore said.
Even in that small time since the approval of that first immunotherapy, the field has already seen changes.